197 Female sex and mortality in SAB 9 All patients N= 3384 Female patients N= 1431 Male patients N= 1953 p-value a Route of acquisition, n (%) 0.009 Hospital acquired 920 (27.2) 405 (28.4) 515 (26.4) Healthcare associated 1878 (55.6) 810 (56.8) 1068 (54.8) Community acquired 579 (17.1) 212 (14.9) 367 (18.8) Persistence Persistent bacteremia d, n (%) 1269 (37.5) 517 (36.1) 752 (38.5) 0.161 No. of days positive blood cultures, median (IQR) 1 (1-4) 1 (1-4) 1 (1-4) 0.210 Disease management TTE performed, n (%) 2540 (75.3) 1057 (74.0) 1483 (76.2) 0.158 TEE performed, n (%) 1297 (38.4) 495 (34.6) 802 (41.1) <0.001 Duration of antibiotics, median (IQR) 28 (14-44) 24 (14-42) 28 (14-45) 0.005 Intervention performed e, n (%) 1656 (49.1) 702 (49.3) 954 (48.9) 0.834 Clinical outcomes, n (%) Metastatic infection 1325 (39.2) 512 (35.8) 813 (41.6) 0.001 Recurrent bacteremia f 317 (9.4) 147 (10.3) 170 (8.7) 0.135 Mortality 30 days 682 (20.2) 301 (21.0) 381 (19.5) 0.278 Mortality 90 days 879 (26.0) 388 (27.1) 491 (25.1) 0.204 Values are counts (%) for categorical variables and medians (interquartile ranges) for continuous variables. APS assessed at time of patient’s first blood culture. APS, acute physiology score; IQR, interquartile range; MRSA, methicillin-resistant Staphylococcus aureus; TEE, transesophageal echocardiography; TTE, transthoracic echocardiography. a Fisher’s exact, Mann-Whitney U, and Pearson Chi-Square tests were used in the analyses. b USA300 status was missing in 248 (7%) patients. For all other variables, missing data was <3%. c More than 14 days of symptoms was set as 14 days. d Defined as 3 days or more of positive blood cultures. e Whether an intervention was performed to treat the bacteraemia (e.g. surgery, drainage, line or device removal). f Recurrent SAB means recurrence after this first SAB episode.
RkJQdWJsaXNoZXIy MTk4NDMw